The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question. Therefore,...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Ronald G. Hall, Travis J. Cole, Chip Shaw, Carlos A. Alvarez
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2022-02-01
Reeks:	Antibiotics
Onderwerpen:	fidaxomicin vancomycin <i>Clostridioides difficile</i> CDI recurrence
Online toegang:	https://www.mdpi.com/2079-6382/11/3/295
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!